Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:affects |
pharmacokinetics
pharmacodynamics bioactivity |
| gptkbp:appliesTo |
drugs
proteins peptides |
| gptkbp:canBe |
random
reversible targeted site-specific irreversible branched PEG linear PEG multi-arm PEG non-specific |
| gptkbp:cause |
reduced activity
altered binding affinity |
| gptkbp:commonReagent |
NHS-PEG
mPEG maleimide-PEG |
| gptkbp:firstDescribed |
1977
|
| https://www.w3.org/2000/01/rdf-schema#label |
PEGylation
|
| gptkbp:improves |
half-life
|
| gptkbp:involves |
gptkb:plastic
|
| gptkbp:method |
covalent attachment
|
| gptkbp:purpose |
increase stability
increase solubility prolong circulation time reduce immunogenicity |
| gptkbp:reduces |
toxicity
immunogenicity proteolytic degradation antigenicity renal clearance |
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
| gptkbp:relatedTo |
histone modification
bioconjugation |
| gptkbp:usedFor |
gptkb:pegfilgrastim
gptkb:peginterferon_beta-1a interferon alpha pegaspargase peginterferon lambda |
| gptkbp:usedIn |
drug delivery
biopharmaceuticals therapeutic proteins |
| gptkbp:bfsParent |
gptkb:polyethylene_glycol_(PEG)
|
| gptkbp:bfsLayer |
8
|